Two studies of older adults with type 2 diabetes linked diabetic retinal disease with higher dementia risk. DME and more severe diabetic retinopathy were associated with higher all-cause and vascular dementia risk, but not consistently with Alzheimer’s disease.
The FDA approved an updated Vabysmo label for macular edema following retinal vein occlusion beyond six months. The decision extends treatment based on data showing visual acuity gains and central subfield thickness reductions maintained through week 72.
AAV-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment for neovascular AMD, with leading clinical candidates including RGX-314, ADVM-022, 4D-150, and NG101.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07705607 |
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07705555 |
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) |
NOT_YET_RECRUITING | PHASE3 |
| NCT06962839 |
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema |
RECRUITING | PHASE2 |
| NCT06825702 |
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema |
RECRUITING | PHASE2 |
